Series E and E1 Warrant Exercises Secure $16.3 Million for Delcath Systems Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company dedicated to treating primary and metastatic liver cancers, announced…
CEL-SCI Prices $5 Million Public Offering CEL-SCI Corporation (NYSE American: CVM), a clinical-stage immunotherapy company focused on cancer treatments, today announced the pricing of a public offering of 16,130,000 shares…
HCA Healthcare Appoints Wendy Warren as SVP & Chief Ethics Officer HCA Healthcare, Inc. (NYSE: HCA), one of the nation’s leading healthcare providers, has announced the appointment of Wendy Warren…
Kerecis Expands Silicone Fish-Skin Line with SurgiClose® Kerecis, a leader in the use of sustainably sourced fish skin and fatty acids for cellular therapy, tissue regeneration, and protection, has announced…
Digital Health Tools Expanding to Support Patient Care, Reports IQVIA Despite a decline in venture funding for digital health companies over the past two and a half years, digital health…
Kidney disease: Proton Intelligence raises $6.95M for potassium monitoring trials Proton Intelligence Inc., the developer of the innovative Continuous Potassium Monitoring (CKM™) platform, has successfully closed a $6.95 million USD…
Cardinal Health (NYSE: CAH) has announced the initiation of weekly actinium-225 (Ac-225) production at its Center for Theranostics Advancement in Indianapolis, Indiana. This milestone follows a collaboration with TerraPower Isotopes…
HCA Healthcare, Inc. (NYSE: HCA), a leading healthcare provider in the United States, has announced the appointment of Wendy Warren as senior vice president and chief ethics and compliance officer,…
Pfizer Inc. (NYSE: PFE) has announced that the U.S. Food and Drug Administration (FDA) has granted approval for BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and mFOLFOX6 (fluorouracil,…
Quantum-Si Incorporated (Nasdaq: QSI), known as The Protein Sequencing Company™, has announced the submission of a new preprint paper to BioRxiv, showcasing the power of its proprietary bioinformatics tool, ProteoVue,…
Axoft, a neurotechnology company, has announced the approval of its first-in-human clinical study, set to begin in early 2025 at The Panama Clinic. The study will explore the usability of…
Valink Therapeutics, a biopharmaceutical company focused on the discovery and development of bispecific antibody-drug conjugates (bsADCs) to treat cancer and other diseases, has announced the appointment of Martin D. Williams…